Abstract
An efficient route for the synthesis of novel bis(1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile) derivatives is reported. The synthetic pathway involves one pot, synthesis of bis-aldehydes, malononitrile, and pyrazolone in the presence of pyridine. The anticancer activity of the synthesized products against MCF7, HEPG2, and A549 cell lines was assessed. Docking studies were performed and indicated the best binding mode compared to the standard ligand sorafenib.
Keywords:
Bis(1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile); Bis-aldehydes; Bis-arylidenemalononitriles; Cytotoxic assay; Docking studies; MTT; Malononitrile; Multicomponent reactions.
Copyright © 2017 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
A549 Cells
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / chemistry*
-
Antineoplastic Agents / pharmacology*
-
Breast / drug effects
-
Breast / metabolism
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / metabolism
-
Female
-
Hep G2 Cells
-
Humans
-
MCF-7 Cells
-
Molecular Docking Simulation
-
Neoplasms / drug therapy
-
Neoplasms / metabolism
-
Nitriles / chemical synthesis
-
Nitriles / chemistry*
-
Nitriles / pharmacology*
-
Pyrazoles / chemical synthesis
-
Pyrazoles / chemistry*
-
Pyrazoles / pharmacology*
-
Vascular Endothelial Growth Factor Receptor-2 / metabolism
Substances
-
Antineoplastic Agents
-
Nitriles
-
Pyrazoles
-
Vascular Endothelial Growth Factor Receptor-2